Monoclonal antibodies lock down SARS-CoV-2 spike.

Huang H, Angeletti D

Trends Immunol 44 (11) 874-876 [2023-11-00; online 2023-10-05]

SARS-CoV-2 rapidly accumulated mutations in its immunodominant receptor-binding domain (RBD), rendering all clinically authorized monoclonal antibodies (mAbs) ineffective. Liu et al. unveil potent human mAbs that neutralize all tested SARS-CoV-2 variants by locking the Spike protein RBD in a downward conformation, thus inhibiting receptor engagement.

Category: Post-COVID

Category: Vaccines

Funder: KAW/SciLifeLab

Funder: VR

Type: Journal article

PubMed 37805348

DOI 10.1016/

Crossref 10.1016/

pii: S1471-4906(23)00202-8

Publications 9.5.0